1 | phase | 31,094 |
2 | rome | 326 |
3 | euroaspire | 61 |
4 | ncep/atp | 10 |
5 | timi-flow | 7 |
6 | hui-mark | 6 |
7 | sm-a*-sm-c* | 6 |
8 | uroplakin | 6 |
9 | 'phase | 5 |
10 | -phase | 5 |
11 | cefalosporin | 5 |
12 | lauge-hanson | 5 |
13 | pre-phase | 5 |
14 | prometaphase | 5 |
15 | souvenir | 5 |
16 | kake | 4 |
17 | afm-fm | 3 |
18 | fold-type | 3 |
19 | arsenazo | 2 |
20 | iatroref | 2 |
21 | infancy-childhood | 2 |
22 | jeneric | 2 |
23 | nct00276068 | 2 |
24 | pentium | 2 |
25 | t-scan | 2 |
26 | 1,104bp | 1 |
27 | 223-bp | 1 |
28 | 256-bp | 1 |
29 | 554-bp | 1 |
30 | 678-bp | 1 |
31 | aphase | 1 |
32 | apostel | 1 |
33 | audience-size | 1 |
34 | batatasin | 1 |
35 | benthic-pelagic | 1 |
36 | caspase-glo™ | 1 |
37 | ch2tbu | 1 |
38 | chikusetsusaponin | 1 |
39 | cml-studies | 1 |
40 | csf-talin | 1 |
41 | daughter-to-mother | 1 |
42 | dexylosyltubeimoside | 1 |
43 | diabedes | 1 |
44 | diarylcomosols | 1 |
45 | double-blind-phase | 1 |
46 | emras | 1 |
47 | enolic-h | 1 |
48 | epoxydiene | 1 |
49 | eurospire | 1 |
50 | figo-stages | 1 |
51 | g1/s-phase | 1 |
52 | groups.resultsat | 1 |
53 | groupsafter | 1 |
54 | ii-to-anaphase | 1 |
55 | iib/ | 1 |
56 | iib/gp | 1 |
57 | impressions-part | 1 |
58 | infliximab- | 1 |
59 | leaving-group | 1 |
60 | methotrexate-to-ustekinumab | 1 |
61 | nsaids/cox | 1 |
62 | oddba | 1 |
63 | optimax | 1 |
64 | reduction*madit | 1 |
65 | siami | 1 |
66 | thaoa/hwcg | 1 |
67 | treatment.grade | 1 |
68 | venticis | 1 |
69 | wenfeng | 1 |
70 | wt+ang | 1 |
71 | α″→β | 1 |
1 | 'phase | 5 |
2 | -phase | 5 |
3 | 1,104bp | 1 |
4 | 223-bp | 1 |
5 | 256-bp | 1 |
6 | 554-bp | 1 |
7 | 678-bp | 1 |
8 | afm-fm | 3 |
9 | aphase | 1 |
10 | apostel | 1 |
11 | arsenazo | 2 |
12 | audience-size | 1 |
13 | batatasin | 1 |
14 | benthic-pelagic | 1 |
15 | caspase-glo™ | 1 |
16 | cefalosporin | 5 |
17 | ch2tbu | 1 |
18 | chikusetsusaponin | 1 |
19 | cml-studies | 1 |
20 | csf-talin | 1 |
21 | daughter-to-mother | 1 |
22 | dexylosyltubeimoside | 1 |
23 | diabedes | 1 |
24 | diarylcomosols | 1 |
25 | double-blind-phase | 1 |
26 | emras | 1 |
27 | enolic-h | 1 |
28 | epoxydiene | 1 |
29 | euroaspire | 61 |
30 | eurospire | 1 |
31 | figo-stages | 1 |
32 | fold-type | 3 |
33 | g1/s-phase | 1 |
34 | groups.resultsat | 1 |
35 | groupsafter | 1 |
36 | hui-mark | 6 |
37 | iatroref | 2 |
38 | ii-to-anaphase | 1 |
39 | iib/ | 1 |
40 | iib/gp | 1 |
41 | impressions-part | 1 |
42 | infancy-childhood | 2 |
43 | infliximab- | 1 |
44 | jeneric | 2 |
45 | kake | 4 |
46 | lauge-hanson | 5 |
47 | leaving-group | 1 |
48 | methotrexate-to-ustekinumab | 1 |
49 | ncep/atp | 10 |
50 | nct00276068 | 2 |
51 | nsaids/cox | 1 |
52 | oddba | 1 |
53 | optimax | 1 |
54 | pentium | 2 |
55 | phase | 31,094 |
56 | pre-phase | 5 |
57 | prometaphase | 5 |
58 | reduction*madit | 1 |
59 | rome | 326 |
60 | siami | 1 |
61 | sm-a*-sm-c* | 6 |
62 | souvenir | 5 |
63 | t-scan | 2 |
64 | thaoa/hwcg | 1 |
65 | timi-flow | 7 |
66 | treatment.grade | 1 |
67 | uroplakin | 6 |
68 | venticis | 1 |
69 | wenfeng | 1 |
70 | wt+ang | 1 |
71 | α″→β | 1 |
1 | sm-a*-sm-c* | 6 |
2 | infliximab- | 1 |
3 | iib/ | 1 |
4 | nct00276068 | 2 |
5 | oddba | 1 |
6 | methotrexate-to-ustekinumab | 1 |
7 | benthic-pelagic | 1 |
8 | jeneric | 2 |
9 | infancy-childhood | 2 |
10 | treatment.grade | 1 |
11 | dexylosyltubeimoside | 1 |
12 | kake | 4 |
13 | rome | 326 |
14 | epoxydiene | 1 |
15 | fold-type | 3 |
16 | euroaspire | 61 |
17 | eurospire | 1 |
18 | phase | 31,094 |
19 | 'phase | 5 |
20 | -phase | 5 |
21 | double-blind-phase | 1 |
22 | pre-phase | 5 |
23 | g1/s-phase | 1 |
24 | aphase | 1 |
25 | ii-to-anaphase | 1 |
26 | prometaphase | 5 |
27 | audience-size | 1 |
28 | iatroref | 2 |
29 | thaoa/hwcg | 1 |
30 | wt+ang | 1 |
31 | wenfeng | 1 |
32 | enolic-h | 1 |
33 | siami | 1 |
34 | hui-mark | 6 |
35 | apostel | 1 |
36 | afm-fm | 3 |
37 | pentium | 2 |
38 | t-scan | 2 |
39 | uroplakin | 6 |
40 | csf-talin | 1 |
41 | chikusetsusaponin | 1 |
42 | cefalosporin | 5 |
43 | batatasin | 1 |
44 | lauge-hanson | 5 |
45 | arsenazo | 2 |
46 | 223-bp | 1 |
47 | 554-bp | 1 |
48 | 256-bp | 1 |
49 | 678-bp | 1 |
50 | 1,104bp | 1 |
51 | iib/gp | 1 |
52 | ncep/atp | 10 |
53 | leaving-group | 1 |
54 | daughter-to-mother | 1 |
55 | groupsafter | 1 |
56 | souvenir | 5 |
57 | emras | 1 |
58 | diabedes | 1 |
59 | figo-stages | 1 |
60 | cml-studies | 1 |
61 | venticis | 1 |
62 | diarylcomosols | 1 |
63 | groups.resultsat | 1 |
64 | reduction*madit | 1 |
65 | impressions-part | 1 |
66 | ch2tbu | 1 |
67 | timi-flow | 7 |
68 | optimax | 1 |
69 | nsaids/cox | 1 |
70 | caspase-glo™ | 1 |
71 | α″→β | 1 |